Hepatitis C Disease Forecast and Market Analysis to 2035 – Forecasts, Treatment, Marketed Drugs, Pricing, Reimbursement, and Access & Pipeline – ResearchAndMarkets.com

DUBLIN–()–The “Hepatitis
C Disease Forecast and Market Analysis to 2035”
report has been
added to ResearchAndMarkets.com’s offering.

Hepatitis C is a blood-borne liver disease caused by the hepatitis C
virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a
communicable disease spread primarily through direct contact with the
blood or the bodily fluids of an infected individual, including sexual
and mother-to-child transmission. Hepatitis C infection normally does
not produce signs or symptoms and, as such, most people who are infected
do not know they have the disease.

Market Snapshot

  • Falling disease prevalence and anticipated price decreases as
    competition intensifies will drive a net decline in market value.
  • Harvoni remains the dominant option for GT-1/4 patients, but has ceded
    share to cheaper rivals as competition intensifies.
  • Cases are expected to decline, driven by complexities in high-risk
    populations, demographics, and treatment developments.
  • Mavyret’s approval at a substantial discount to Epclusa paves the way
    for a further decline in Gilead’s HCV revenues.
  • Lack of unmet need and declining market value prompts Johnson &
    Johnson and Merck & Co to discontinue pipeline regimens.
  • Pricing is the key differentiator for drugs in this market.

Key Topics Covered:

Forecast: Hepatitis C

  • Executive Summary
  • Market Dynamics
  • Forecast and Future Trends
  • Market Definition and Methodology
  • Primary Research Methodology
  • Bibliography
  • Product Profile: Daklinza
  • Product Profile: Epclusa
  • Product Profile: Harvoni
  • Product Profile: Mavyret
  • Product Profile: Sovaldi
  • Product Profile: Viekira Pak Franchise
  • Product Profile: Vosevi
  • Product Profile: Ximency
  • Product Profile: Zepatier

Treatment: Hepatitis C

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
  • Unmet Needs In Hepatitis C

Epidemiology: Hepatitis C in the US, Japan, and 5EU

  • Executive Summary
  • Disease Overview
  • Sources And Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths And Limitations
  • Bibliography

Marketed Drugs: Hepatitis C

  • Executive Summary
  • Product Overview
  • Product Profile: Daklinza
  • Product Profile: Epclusa
  • Product Profile: Harvoni
  • Product Profile: Mavyret
  • Product Profile: Sovaldi
  • Product Profile: Viekira Pak Franchise
  • Product Profile: Vosevi
  • Product Profile: Ximency
  • Product Profile: Zepatier

Hepatitis C Pricing, Reimbursement, and Access

  • Executive Summary
  • Regulatory Labels
  • Payer Archetypes
  • Access to Recently Launched and Pipeline Products
  • Evidentiary Requirements and Future Pipeline Potential
  • US Pricing
  • US Reimbursement
  • Japan
  • Pricing in the Five Major EU Markets
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Methodology

Pipeline: Hepatitis C

  • Executive Summary
  • Pipeline Trends

For more information about this report visit https://www.researchandmarkets.com/research/c6sgc2/hepatitis_c?w=4.



Source link

more recommended stories

Social Media Auto Publish Powered By : XYZScripts.com
%d bloggers like this: